Sun Pharmaceutical Industries’ shares slipped more than 2% after the company disclosed that the US Food and Drug Administration (US FDA) has classified its Baska manufacturing facility under Official Action Indicated (OAI) following a recent inspection. As of 9:29AM, the shares were trading 2.15% lower at Rs 1,754.30.
According to the company’s regulatory filing, the US FDA conducted an inspection at Sun Pharma’s Baska facility between September 8 and September 19, 2025. After reviewing the findings, the regulator assigned an OAI status, which indicates that certain issues were identified that may require regulatory action.
Sun Pharma clarified that despite the OAI classification, it continues to manufacture and supply approved products from the Baska facility to the US market. The company also stated that it is working closely with the US FDA to address the observations and achieve full compliance.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
